Lasmiditan is a medicinal product currently in clinical development for the acute treatment of migraine. A migraine is usually a moderate or severe headache felt as a throbbing pain on one side of the head. Many people also have symptoms such as nausea, vomiting and increased sensitivity to light or sound. Migraines may be with aura (specific warning signs just before the migraine begins, such as seeing flashing lights), although the most common type is without aura (no specific warning signs).
Lasmiditan presumably exerts its therapeutic action in the treatment of migraine through effects at a specific serotonin receptor called 5-HT1F; however, the precise mechanism is unknown. If licenced, lasmiditan will offer an additional option for first and/or second-line acute treatment of migraine with or without aura in adults.
Levodopa, carbidopa monohydrate and entacapone intestinal gel (LECIG, TRICEL, Lecigon) is in development to treat severe motor fluctuations in advanced Parkinson’s disease (PD). PD is a progressive neurological disease caused by a loss of nerve cells in a particular part of the brain that results in decreased levels of the chemical messenger dopamine. This results …